These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 21815133)

  • 1. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
    McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
    Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
    Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
    Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.